A new study explores the cholesterol-lowering effects of a new drug called enlicitide. Nicole Mason/Stocksy A recent study, published in JAMA on November 9, investigates a drug called enlicitide. The ...

A new daily pill could reduce bad cholesterol levels by 60%, according to a new study. Enlicitide, which was developed by Merck, lowered “bad” LDL cholesterol by more than half in a global study ...

Enlicitide decanoate, an oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; longer-term data ...

Enlicitide has the potential to be the first approved oral PCSK9 inhibitor designed to deliver antibody-like efficacy and help address critical unmet needs for patients with HeFH to help combat the ...

A powerful new treatment has emerged in efforts to reduce high cholesterol levels and the associated risk of heart health problems. In a new trial, the drug enlicitide decanoate was found to lower ...

An experimental once-daily pill called enlicitide cut LDL cholesterol by 57% in a large Phase 3 clinical trial, a result researchers say could expand options for patients who struggle with existing ...

(RTTNews) - Merck & Co Inc. (MRK) has unveiled the first results from its pivotal Phase 3 CORALreef Lipids trial, highlighting the efficacy of enlicitide decanoate, an investigational once-daily oral ...

A new daily pill could reduce bad cholesterol levels by 60%, according to a new study. Enlicitide, which was developed by Merck, lowered "bad" LDL cholesterol by more than half in a global study ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef HeFH trial ...

A once-a-day tablet called enlicitide is reshaping expectations for cholesterol care, cutting low density lipoprotein, or “bad,” cholesterol by about 60% in large clinical trials. Instead of ...